COVID-19 Investigational Treatments in Use Among Hospitalized Patients Identified Through the US Coronavirus Disease 2019–Associated Hospitalization Surveillance Network, March 1–June 30, 2020

Details

• Alternative Title:
  Open Forum Infect Dis
• Personal Author:
  Acosta, Anna M ; Mathis, Adria L ; Budnitz, Daniel S ; Geller, Andrew I ; Chai, Shua J ; Alden, Nisha B ; Meek, James ; Anderson, Evan J ; Ryan, Patricia ; Kim, Sue ; Como-Sabetti, Kathryn ; Torres, Salina ; Dufort, Elizabeth ; Bennett, Nancy M ; Billing, Laurie M ; Sutton, Melissa ; Keipp Talbot, H ; George, Andrea ; Pham, Huong ; Hall, Aron J ; Fry, Alicia ; Garg, Shikha ; Kim, Lindsay
• Description:
  Using a coronavirus disease 2019 (COVID-19)-associated hospitalization surveillance network, we found that 42.5% of hospitalized COVID-19 cases with available data from March 1-June 30, 2020, received ≥1 COVID-19 investigational treatment. Hydroxychloroquine, azithromycin, and remdesivir were used frequently; however, hydroxychloroquine and azithromycin use declined over time, while use of remdesivir increased.
• Subjects:
  AcademicSubjects/MED00290 Brief Report Coronavirus Editor's Choice Hospitalization Therapeutics
• Source:
  Open Forum Infect Dis. 2020; 7(11)
• Pubmed ID:
  33274249
• Pubmed Central ID:
  PMC7686662
• Document Type:
  Journal Article
• Volume:
  7
• Issue:
  11
• Collection(s):
  CDC Public Access
• Main Document Checksum:
  urn:sha256:0deebca69fa556da226d68e2c8f4ef657d81c9eda898187873f9764c5ae0f2dc
• Download URL:
  https://stacks.cdc.gov/view/cdc/98895/cdc_98895_DS1.pdf
• File Type:
  [PDF - 286.37 KB ]